title: [Drug-induced NASH].
abstract: Steatohepatitis is pathologically characterized by zone 3-dominant hepatic steatosis with ballooned hepatocytes and Mallory bodies, zone 3 pericellular and perivenular fibrosis with or without bridging fibrosis, and lobular inflammatory cell infiltration. Alcoholic hepatitis is a prototype of this syndrome, but a variety of diseases such as obesity, diabetes mellitus, Wilson disease and hepatitis C could reveal very similar pathological changes in some occasions. Therefore, well defined diseases need to be excluded in the process of differential diagnosis of steatohepatitis. Pathways possibly involved in the development of drug-induced steatohepatitis were categorized into four and outlines of the possible mechanisms involved in the development of this syndrome were proposed in this article.
authors.affiliation: Department of Gastroenterology and Hepatology, Kochi Medical School.
authors.forename: Toshiji
authors.initials: T
authors.lastname: Saibara
authors.forename: Saburo
authors.initials: S
authors.lastname: Onishi
mesh_terms: D000638:Amiodarone / Q000009:adverse effects*; D005227:Fatty Acids / Q000378:metabolism; D005234:Fatty Liver / Q000139:chemically induced* / Q000453:epidemiology; D006801:Humans; D010084:Oxidation-Reduction; D013629:Tamoxifen / Q000009:adverse effects*
chemical_list: D005227:Fatty Acids; D013629:Tamoxifen; D000638:Amiodarone